Shire obtains preliminary injunction against Roche over emicizumab

Date: 2017-07-11   Author: Pankaj Singh  Category: #news

Shire obtains preliminary injunction against Roche over emicizumab

Renowned specialty biopharma giant Shire Plc, has been granted legal rights by the Hamburg court to injunct Swiss drug maker and arch rival Roche, regarding emicizumab, also called ACE910, the reputed hemophilia treatment drug. Headquartered in Dublin, Shire has watched its shares plummet over the course of last year as Roche surged ahead in the battle over emicizumab. Shire has fought back, making alleged claims against Roche, with regards to the effectiveness and safety factor of emicizumab. In fact, as per an official statement released by the massive pharmaceutical market player, the company has sought this injunction to avoid any further propagation of incorrect depiction regarding the adverse events that took place in the HAVEN 1 emicizumab Phase 3 trial.

Reliable sources cite that Shire accused Roche of misleading patients and making false statements regarding the hazardous effects of emicizumab recorded in its clinical trials. In defense, Roche has specified that the company is committed to taking decisions in favor of patients. Disregarding the claims made against it by Shire, Roche has stood firm regarding the clinical trial protocol of emicizumab.

Certain reports state that Shire has taken this stand as an interim measure to circulate accurate and sufficient information regarding the phase 3 clinical trials of emicizumab conducted by Roche. In all likelihood, this action undertaken by Shire is likely to generate awareness among patients and physicians regarding the efficacy of the drug.

Shire’s claims against Roche may have stemmed from analysts’ findings regarding adverse events in Roche’s studies, including thrombotic microangiopathy - which essentially signifies blood vessel damage in vital organs. A report from an unclaimed source had even stated that a patient had lost his life due to rectal hemorrhage, after being treated with emicizumab. Roche rubbished the reports and took an unyielding stand with regards to the effectiveness of emicizumab. This has been proved by the company’s statement recorded last month, wherein it has been claiming that emicizumab has cut down the bleed rate by 87% in patients who resist standard therapies as opposed to those who were treated with other drugs.

The reputed Swiss drug maker has been looking forward to amassing a chunk of the 11-billion-dollar hemophilia drug market with massive sales of emicizumab. To compete with the traditional treatments offered by Novo Nordisk and Shire, it has been reported that Roche will also involve itself in developing new drugs with a successful clinical trial rate.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

3D Visualization System Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2027

Author: Ashwin Naphade

The and United States 3D Visualization System Market Forecast Report provides details analysis of and United States 3D Visualization System industry which will accelerate your business. and United States 3D Visualization System market report cover...


3D Systems Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2027

Author: Ashwin Naphade

and China 3D Systems Market Trends covers the companies’ data including Growth potential analysis, Industry segmentation, Business trends, Growth drivers, Price trend analysis. The Report also Gives Detail Analysis on Market concern Like an...


Cinema Ticketing System Service Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2027

Author: Ashwin Naphade

and United States Cinema Ticketing System Service Market report provides key statistics on the market status of the and United States Cinema Ticketing System Service Industry and is a valuable source of guidance and direction for companies and in...